{"transactions":[{"id":2038568,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2023-02-01T20:30:11.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":69531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":69531,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":69531},"source":{"system":"sec-edgar","filing":"0001209191-23-006046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919123006046/doc4.xml","form_type":"4"}},{"id":2263764,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-19T07:00:11.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":5100,"price":0.19,"value":969.0,"ownership":{"direct":true},"balance_after":97191,"source":{"system":"sec-edgar","filing":"0001209191-22-030307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919122030307/doc4.xml","form_type":"4"}},{"id":2314233,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2022-03-30T17:15:42.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":713132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":713132,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":713132},"source":{"system":"sec-edgar","filing":"0001209191-22-021622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919122021622/doc4.xml","form_type":"4"}},{"id":2754371,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-04-07T16:05:10.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":50000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-025842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919121025842/doc4.xml","form_type":"4"}},{"id":2953514,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-08T07:04:44.000Z","date":"2020-12-04","kind":"sale","acquired":false,"shares":71519,"price":0.83,"value":59360.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units  which were granted to the Reporting Person on April 9, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":92091,"source":{"system":"sec-edgar","filing":"0001209191-20-062113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120062113/doc4.xml","form_type":"4"}},{"id":3100935,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2020-06-24T08:21:51.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":2874,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2152,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":2874},"source":{"system":"sec-edgar","filing":"0001209191-20-038680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120038680/doc4.xml","form_type":"4"}},{"id":3100934,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-24T08:21:51.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":2874,"price":0.87,"value":2500.38,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":163610,"source":{"system":"sec-edgar","filing":"0001209191-20-038680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120038680/doc4.xml","form_type":"4"}},{"id":3114879,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T07:36:29.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":4.372,"price":1143.68,"value":5000.16896,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":5175},"source":{"system":"sec-edgar","filing":"0001209191-20-035436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120035436/doc4.xml","form_type":"4"}},{"id":3114878,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-10T07:36:29.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":5175,"price":0.87,"value":4502.25,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":160736,"source":{"system":"sec-edgar","filing":"0001209191-20-035436","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120035436/doc4.xml","form_type":"4"}},{"id":3177994,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-04-13T16:35:41.000Z","date":"2020-04-09","kind":"grant","acquired":true,"shares":123064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."}],"balance_after":155561,"source":{"system":"sec-edgar","filing":"0001209191-20-024209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120024209/doc4.xml","form_type":"4"}},{"id":3345356,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2019-12-11T17:51:33.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":5026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock."}],"balance_after":5026,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":5026},"source":{"system":"sec-edgar","filing":"0001209191-19-060089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919119060089/doc4.xml","form_type":"4"}},{"id":3345355,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-11T17:51:33.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":4.372,"price":1143.68,"value":5000.16896,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%.  The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A preferred stock has no expiration date."}],"balance_after":4.372,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":5026},"source":{"system":"sec-edgar","filing":"0001209191-19-060089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919119060089/doc4.xml","form_type":"4"}},{"id":3345354,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-11T17:51:33.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":611994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date."}],"balance_after":611994,"derivative":{"exercise_price":0.9,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":611994},"source":{"system":"sec-edgar","filing":"0001209191-19-060089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919119060089/doc4.xml","form_type":"4"}},{"id":3729150,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2018-12-17T16:36:03.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in three equal annual installments beginning on December 13, 2019."}],"balance_after":125000,"derivative":{"exercise_price":2.25,"expiration_date":"2026-12-13","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-062948","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919118062948/doc4.xml","form_type":"4"}},{"id":3763295,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Convertible Promissory Note","published_at":"2018-11-15T16:17:25.000Z","date":"2018-11-13","kind":"exercise","acquired":false,"price":10000,"reported_value":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Convertible Promissory Note (the \"Note\"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%."}],"derivative":{"exercise_price":1.68,"expiration_date":"2018-12-31","underlying":"Common Stock","underlying_shares":5953},"source":{"system":"sec-edgar","filing":"0001209191-18-058719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919118058719/doc4.xml","form_type":"4"}},{"id":3763294,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-15T16:17:25.000Z","date":"2018-11-13","kind":"exercise","acquired":true,"shares":5953,"price":1.68,"value":10001.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2)."}],"balance_after":32497,"source":{"system":"sec-edgar","filing":"0001209191-18-058719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919118058719/doc4.xml","form_type":"4"}},{"id":3878922,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2018-07-02T19:33:22.000Z","date":"2018-06-28","kind":"grant","acquired":true,"shares":2480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Warrants were issued for no additional consideration in connection with the offer and sale of the Note."}],"balance_after":2480,"derivative":{"exercise_price":2.52,"exercise_date":"2018-12-28","expiration_date":"2021-06-28","underlying":"Common Stock","underlying_shares":2480},"source":{"system":"sec-edgar","filing":"0001209191-18-040507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919118040507/doc4.xml","form_type":"4"}},{"id":3878921,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Convertible Promissory Note","published_at":"2018-07-02T19:33:22.000Z","date":"2018-06-28","kind":"grant","acquired":true,"price":10000,"reported_value":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Convertible Promissory Note (the \"Note\") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a \"Qualified Financing\"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1)."}],"derivative":{"expiration_date":"2018-12-31","underlying":"Common Stock","underlying_shares":4961},"source":{"system":"sec-edgar","filing":"0001209191-18-040507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919118040507/doc4.xml","form_type":"4"}},{"id":4271161,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-06-28T16:14:49.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":31960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025."}],"balance_after":31960,"derivative":{"exercise_price":4.55,"expiration_date":"2025-05-12","underlying":"Common Stock","underlying_shares":31960},"source":{"system":"sec-edgar","filing":"0001209191-17-042112","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117042112/doc4a.xml","form_type":"4/A","original_submission_date":"2013-06-13"}},{"id":4283956,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-06-13T16:43:31.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":31960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018."}],"balance_after":31960,"derivative":{"exercise_price":4.55,"expiration_date":"2022-05-12","underlying":"Common Stock","underlying_shares":31960},"source":{"system":"sec-edgar","filing":"0001209191-17-039505","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117039505/doc4.xml","form_type":"4"}},{"id":4308375,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-05-23T18:00:49.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":307310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025."}],"balance_after":307310,"derivative":{"exercise_price":5,"expiration_date":"2025-05-12","underlying":"Common Stock","underlying_shares":307310},"source":{"system":"sec-edgar","filing":"0001209191-17-034730","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117034730/doc4a.xml","form_type":"4/A","original_submission_date":"2017-05-16"}},{"id":4318475,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-05-16T21:13:25.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":307310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018."}],"balance_after":307310,"derivative":{"exercise_price":5,"expiration_date":"2022-05-12","underlying":"Common Stock","underlying_shares":307310},"source":{"system":"sec-edgar","filing":"0001209191-17-032894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117032894/doc4.xml","form_type":"4"}},{"id":4318474,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Convertible Promissory Note","published_at":"2017-05-16T21:13:25.000Z","date":"2017-05-12","kind":"exercise","acquired":false,"price":0,"reported_value":37163,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a\nconversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering."}],"derivative":{"exercise_price":1.4,"expiration_date":"2017-05-12","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001209191-17-032894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117032894/doc4.xml","form_type":"4"}},{"id":4318473,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-05-16T21:13:25.000Z","date":"2017-05-12","kind":"exercise","acquired":true,"shares":26544,"price":1.4,"value":37161.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2)."}],"balance_after":26544,"source":{"system":"sec-edgar","filing":"0001209191-17-032894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919117032894/doc4.xml","form_type":"4"}}]}